Overall rank by patents
#34,495
of 49,997 tracked assignees
USPTO PatentsView assignee record - 7 granted patents across 8 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).
The verdict
According to USPTO PatentsView, Biomedtrix ranks #34,495 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 8 technology areas.
USPTO PatentsView assignee plate
Corpus R34495 · US Corporation #34,495 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Bio-Thera Solutions, Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
BioMedtrix · this assignee
34 score
3D Lighting… · lowest
7 score
What this shows Biomedtrix's Innovation Score is 34.4/100 (47th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
BioMedtrix, LLC is a focused PatentsView assignee: 8 CPC subclasses with 71.4% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2023 (2 grants) versus a trough of 1 in 2017. By volume, Biomedtrix sits between Bio Tillion, LLC and BioSure North America LLC.
BioMedtrix, LLC shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Bio Tillion, LLC
7 patents
Bio-Thera Solutions, Ltd.
7 patents
BioChemics, Inc.
7 patents
BioCircuit Technologies, Inc.
7 patents
BioMimetix JV, LLC
7 patents
BioNTech Cell & Gene Therapies GmbH
7 patents
BioStem Technologies, Inc.
7 patents
BioSure North America LLC
7 patents
BioMedtrix, LLC
7 patents
What this shows BioMedtrix holds 7 patents at rank #34,536, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #34,536 in granted patent volume.
Other assignees with the most granted patents in BioMedtrix's primary technology class.
Biomedtrix's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
34 47th percentile higher than 47% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 14.3% |
| 2019 | 1 | 14.3% |
| 2020 | 1 | 14.3% |
| 2021 | 1 | 14.3% |
| 2023 | 2 | 28.6% |
| 2024 | 1 | 14.3% |
Top 8 of 8 technology areas
Overall rank by patents
#34,495
of 49,997 tracked assignees
34.4 out of 100
What to do with this data
BioMedtrix, LLC's patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.